NASDAQ:LBPS

4D pharma (LBPS) Stock Price, News & Analysis

→ You’re invited: Biggest crypto event of 2024 (From InvestorPlace) (Ad)

Free LBPS Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $1.65
▼
$1.65
50-Day Range: $1.56
▼
$3.40
52-Week Range: $1.50
▼
$11.09

Volume: N/A
Average Volume: N/A
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get 4D pharma alerts:

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About 4D pharma

4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom. The company develops therapeutic candidates, including MRx0518 for the treatment of cancer and immune-oncology diseases; MRx-4DP0004 for the treatment of asthma; MRx0029 and MRx0005 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, such as MRx1299 for solid tumors, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. In addition, the company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate MRx0518; strategic collaboration agreement with University of Texas MD Anderson for discovery and development of LBPs in oncology; and Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda, MRx0518 in patients with solid tumors, and to discover and develop LBPs for vaccines. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

LBPS Stock News Headlines

April 15, 2024 | msn.com

4D Molecular Therapeutics new overweight at Barclays on genetic medicine platform

April 8, 2024 | msn.com

Lancashire: pharmacy robots speed up prescription picking

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

March 30, 2024 | yahoo.com

PROGRESS 2024: In business for more than 60 years, Professional Pharmacy offers a wide range of services

March 18, 2024 | msn.com

NAT-STORY4D-Pharmacy first scheme could free up 30 million GP appointments annually

February 13, 2024 | markets.businessinsider.com

Strong Buy Recommendation for 4D Molecular Therapeutics Amid Promising 4D-150 Gene Therapy Study Results

February 8, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), BridgeBio Pharma (BBIO) and Phibro Animal Health (PAHC)

February 5, 2024 | markets.businessinsider.com

Buy Rating for 4D Molecular Therapeutics Backed by Promising 4D-150 Gene Therapy Trial Results

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

February 5, 2024 | marketwatch.com

4D Molecular Therapeutics Shares Rise 33% After Positive Trial Data

November 9, 2023 | msn.com

4D Molecular Therapeutics GAAP EPS of -$0.24 beats by $0.37, revenue of $20.2M beats by $10.98M

August 9, 2023 | msn.com

4D Molecular Therapeutics GAAP EPS of -$0.77 misses by $0.01, revenue of $0.24M misses by $0.78M

July 14, 2023 | benzinga.com

Human Microbiome Market worth $1.7 billion by 2029

May 6, 2023 | benzinga.com

The 4D Bioprinting Market is anticipated to grow at a CAGR of around 35% by 2035, claims Roots Analysis

May 4, 2023 | msn.com

4D Molecular Therapeutics proposes $100M stock offering

March 15, 2023 | msn.com

4D Molecular Therapeutics, Inc. (FDMT) Reports Q4 Loss, Lags Revenue Estimates

February 7, 2023 | finance.yahoo.com

Human Microbiome Market Report 2023-2033

December 15, 2022 | msn.com

How Is The Market Feeling About 4D Molecular Therapeutics?

November 18, 2022 | markets.businessinsider.com

Expert Ratings for 4D Molecular Therapeutics

October 4, 2022 | benzinga.com

Microbiome Therapeutics Market to Boom at Robust CAGR to Cross USD 746 Million by 2028 | BlueWeave Consulting

September 20, 2022 | seekingalpha.com

X4 Pharmaceuticals: Upcoming Catalysts

June 28, 2022 | seekingalpha.com

4D pharma stock to be delisted from Nasdaq after co was placed into administration

June 28, 2022 | finance.yahoo.com

4D pharma plc ("4D pharma") Receives Notice of Delisting From Nasdaq

May 26, 2022 | finance.yahoo.com

4D pharma Presents Trial in Progress Poster on Study of MRx0518 in Combination with BAVENCIO® in Patients with Unresectable Locally Advanced or Metastatic Urothelial Carcinoma at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

May 19, 2022 | finance.yahoo.com

4D pharma to Present at the H.C. Wainwright Global Investment Conference

May 17, 2022 | marketwatch.com

4D pharma Shares Rise on Encouraging Results From Asthma Treatment Trial

May 17, 2022 | nasdaq.com

4D Pharma Presents Data Supporting Potential Of MRx-4DP0004 As Oral Treatment For Asthma

See More Headlines

Receive LBPS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 4D pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/18/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:LBPS
CUSIP: N/A
CIK: 1830162
Web: www.4dpharmaplc.com
Phone: 44-0-11-3895-0130
Fax: N/A
Employees: 92
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: $720,000.00
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Mr. Duncan Joseph Peyton (Age 52)
CEO & Exec. Director
Comp: $302.79k
Dr. Alexander James Stevenson Ph.D. (Age 50)
Chief Scientific Officer & Exec. Director
Comp: $259.88k
Mr. John Brendan Doyle (Age 44)
Chief Financial Officer
Ms. Fay Weston
Head of Investor Relations
Mr. Adrian Murray
Gen. Counsel (Interim)
Mr. Glenn Dourado
Exec. VP of Corp. Devel.
Ms. Lucy Christie
VP of HR
Mr. Christophe Carite
Sr. VP of CMC & Process Devel.
Ms. Imke Mulder
Exec. VP of Research

Key Competitors

View All Competitors

This page (NASDAQ:LBPS) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

4D pharma (LBPS) Stock Price, News & Analysis

About 4D pharma

LBPS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info